Is MK-677 (ibutamoren) worth it for muscle gain?
If you want appetite + a small lean-mass gain on a calorie surplus and you accept the prolactin and insulin-resistance side effects, then yes for a 12 to 16 week run. For pure recomp without weight gain or for elderly muscle-loss prevention, the literature does not support the hype. The 2008 Sevigny Alzheimer's trial showed no functional cognitive benefit despite robust GH and IGF-1 elevation.
Last reviewed · Panya.health editorial
What MK-677 actually does
MK-677 (ibutamoren) is an orally active ghrelin-receptor agonist that elevates pulsatile GH secretion and downstream IGF-1 over weeks to months. Murphy 1998 in J Clin Endocrinol Metab and Nass 2008 in Ann Intern Med both showed sustained elevation of GH and IGF-1 in older adults at 25 mg/day. Lean body mass increased by roughly 1.5 to 2.5 kg over 6 to 12 months in those trials, with the bulk of the change coming from water retention and skeletal muscle in roughly equal parts. Strength gains were modest. The compound is a real ghrelin mimetic, not a placebo; the question is whether the effect size is what the community claims.
When the trade is reasonable
Lean-mass gain on a calorie surplus, alongside resistance training, in a 12 to 16 week cycle. Community dose runs 10 to 25 mg per day, oral, taken at night because of the GH-pulse-during-sleep interaction. Oral bioavailability is genuinely good (around 60 percent), which is the practical advantage over injectable GH-secretagogues. Stop the cycle, give the HPG axis 8 to 12 weeks to normalise, evaluate. For older adults targeting sarcopenia prevention, the evidence is that MK-677 raises lean mass but does NOT improve functional outcomes (gait speed, grip strength, muscle quality) beyond what training alone delivers.
When the trade is bad
Three meaningful side effects under-discussed in vendor-side framing. First: prolactin elevation. About 40 percent of users report elevated prolactin on long cycles, with associated lethargy, low libido, and rarely gynecomastia. Second: insulin resistance. GH elevation drives a real shift toward gluconeogenic state; HbA1c can rise 0.2 to 0.4 percent over a 6-month cycle, which matters if you are pre-diabetic. Third: edema and carpal tunnel symptoms at higher doses (25 mg+). Active or recent cancer is a hard contraindication because IGF-1 elevation is permissive for tumor progression. Pregnancy and breastfeeding: avoid. The Sevigny 2008 trial (Neurology) is also worth knowing about: 12 months of MK-677 in mild Alzheimer's patients raised IGF-1 robustly but produced zero functional cognitive benefit. The hype around 'GH = brain rejuvenation' is not supported.
Where Panya stands
MK-677 is documented at panya.health/peptide/mk-677 with full mechanism, evidence, side-effect profile, and citations. Panya does NOT yet route to vendors for MK-677 because non-GLP-1 vendor scoring is gated on lawyer review. The reconstitution calculator at panya.health/tools/reconstitution-calculator handles dosing math but MK-677 is oral, not injectable, so most users do not need it. Community-mentioned suppliers (Pure Rawz, Sports Technology Labs capsule format, Limitless Life) are listed without endorsement on the documentation page until the affiliate flip closes.
Related posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.